Jagadeesha's brain, the first juvenile Huntington's Disease donation in India, offers hope for vital neurodegenerative research at NIMHANS.

our ability to successfully develop and commercialize products for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease; our ability to successfully ...

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching 'The Other TD' campaignTD is a chronic movement disorder impacting one in four people who take certain pr ...

Neurocrine BiosciencesNBIX shares rose late Tuesday after its bread-and-butter drug, Ingrezza, beat third-quarter ...

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Good day, everyone, and welcome to today's Neurocrine Biosciences Third Quarter 2025 Results Call.

In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2025.

UniQure , said on Monday its experimental gene therapy for Huntington's disease does not have adequate clinical data to ...

CDC warns that a parasitic illness called Chagas disease is now endemic — or always present — in several states. Biting insects called kissing bugs have been identified in 32 states, predominantly in ...

The firm, which had planned to submit a BLA in 2026 for AMT-130, described the FDA's latest feedback as a "drastic change" and "unexpected." ...